New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - clostridium septicum toxoid; clostridium tetani toxoid; clostridium perfringens type d toxoid; clostridium novyi type b toxoid/cells; clostridium chauvoei toxoid/cells - clostridium septicum toxoid 0 vaccine; clostridium tetani toxoid 0 vaccine; clostridium perfringens type d toxoid 0 vaccine; clostridium novyi type b toxoid/cells 0 vaccine; clostridium chauvoei toxoid/cells 0 vaccine - vaccine

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - cloprostenol sodium - cloprostenol sodium 0.25 g/litre - endocrine agent (hormone)

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - dexamethasone - dexamethasone 2 g/litre - endocrine agent (hormone)

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - cephalonium - cephalonium 83.3 g/kg - antibiotic

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - leptospira interrogans serovar hardjoprajitno; leptospira interrogans serovar pomona - leptospira interrogans serovar hardjoprajitno 0 vaccine; leptospira interrogans serovar pomona 0 vaccine - vaccine

United States - English - NLM (National Library of Medicine)

schering plough corporation - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg in 250 ml - avelox is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3 )] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. avelox is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4 )]. avelox is indicated in adult patients for the treatment of complicated skin and ski

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

schering-plough - betamethasone dipropionate, salicylic acid - lotion - 0.064, 2 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

schering-plough, belgium - betamethasone dipropionate - ointment - 0.05 %

European Union - English - EMA (European Medicines Agency)

schering-plough europe - interferon alfa-2b - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b: treatment of adult patients with chronic hepatitis b associated with evidence of hepatitis b viral replication (presence of hbv-dna and hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and/or fibrosis.chronic hepatitis c:adult patients:introna is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv (see section 4.4).the best way to use introna in this indication is in combination with ribavirin.chidren and adolescents:introna is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for serum hcv-rna. the decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, hcv genotype and viral load. the expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - altrenogest - altrenogest 2.2 g/litre - endocrine agent (hormone)